MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Brainstorm Cell Therapeutics Company Profile (NASDAQ:BCLI)

Consensus Ratings for Brainstorm Cell Therapeutics (NASDAQ:BCLI) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.00 (129.36% upside)

Analysts' Ratings History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
DateFirmActionRatingPrice TargetActions
5/11/2016Maxim GroupReiterated RatingBuy$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/25/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha